PRMT5 Inhibition Hits a Nerve (Sheath Tumor): A Targeted Strategy for MPNSTs.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40952693.
- Also identified by DOI 10.1158/1078-0432.CCR-25-2453 and PMC identifier 12481726.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Protein arginine methyltransferase 5 inhibitors represent a promising therapeutic approach for multiple cancers, but their clinical development is hindered by toxicity to normal cells. Synthetic lethality approaches using MTAP-cooperative protein arginine methyltransferase 5 inhibitors offer a compelling strategy that selectively targets cancer cells in nerve sheath sarcomas and other MTAP-deleted tumors. See related article by Zhang et al., p. 4779.
Medical subject headings
- Protein-Arginine N-Methyltransferases
- Enzyme Inhibitors
- Antineoplastic Agents
- Neurofibrosarcoma
- Neurilemmoma